

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

12 January 2011

The Manager Companies
ASX Limited
20 Bridge Street
SYDNEY NSW 2000

(18 pages by email)

Dear Madam,

US BIOTECH SHOWCASE PRESENTATION

Biotron's Managing Director, Dr Michelle Miller, has presented an update of the Company's activities to an international audience at the Biotech Showcase 2011 in San Francisco, USA.


In addition, Dr Miller has given briefings to US institutional investors and pharmaceutical company representatives as part of activities surrounding the annual JP Morgan Healthcare Conference currently underway in San Francisco.

The Biotech Showcase features corporate presentations by 195 innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. The showcase takes place during the week of one of the most important healthcare investor conferences which annually attracts thousands of healthcare and life science business executives to San Francisco.

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV, and also has several earlier stage preclinical and research programs for several other viral infections including influenza, Dengue and Hepatitis B.

Yours faithfully



Peter J. Nightingale
Company Secretary

pjn5802